Close Menu

CE mark

Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

The kit was jointly developed by Singapore's Agency for Science, Technology, and Research, Tan Tock Seng Hospital, and MiRxes.

The two devices can be used to collect saliva specimens for over-the-counter in-home testing kits and prescription-only in vitro diagnostics, respectively.

The test has been validated on many widely available RT-PCR instruments including ones from Thermo Fisher Scientific, Roche, and Qiagen.

The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.

The panel simultaneously tests for SARS-CoV-2 and influenza viruses A and B, while a second analysis detects for human respiratory syncytial virus and human metapneumovirus.

The Maverick instrument enables calibration-free multiplex testing in the field and is supported by cloud-based software.

The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments, according to the company.

The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer.

The PCR test detects SARS-CoV-2, influenza A/B, and respiratory syncytial virus type A and B and runs on the Elite InGenius platform and other major thermcyclers.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.